Denosumab for the prevention of osteoporotic fractures in postmenopausal women.

Health technology assessment (Winchester, England)

Volumn 15 Suppl 1, Issue , 2011, Pages 51-59

  Waugh, N ^a   Royle, P ^b   Scotland, G ^b   Henderson, R ^b   Hollick, R ^b   McNamee, P ^b  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BONE DENSITY CONSERVATION AGENT; DENOSUMAB; MONOCLONAL ANTIBODY; OSTEOCLAST DIFFERENTIATION FACTOR;

CLINICAL TRIAL (TOPIC); COST BENEFIT ANALYSIS; DRUG ANTAGONISM; ECONOMICS; FEMALE; FRAGILITY FRACTURE; HIP FRACTURE; HUMAN; POSTMENOPAUSE OSTEOPOROSIS; PROBABILITY; QUALITY ADJUSTED LIFE YEAR; REVIEW; UNITED NATIONS;

ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; BONE DENSITY CONSERVATION AGENTS; CLINICAL TRIALS AS TOPIC; COST-BENEFIT ANALYSIS; FEMALE; HIP FRACTURES; HUMANS; MARKOV CHAINS; OSTEOPOROSIS, POSTMENOPAUSAL; OSTEOPOROTIC FRACTURES; QUALITY-ADJUSTED LIFE YEARS; RANK LIGAND; UNITED NATIONS;

EID: 84886943003     PISSN: None     EISSN: 20464924     Source Type: Journal    
DOI: 10.3310/hta15suppl1/06     Document Type: Review

References (0)